Overview

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

Status:
Not yet recruiting
Trial end date:
2023-09-13
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate safety and efficacy of a single injection of MIJ821 in addition to standard of care (SoC) pharmacological anti-depressant treatment in participants with treatment-resistant depression (TRD)
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals